Login / Signup

Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.

Elliot J GlotfeltyLars OlsonTobias E KarlssonYazhou LiNigel H Greig
Published in: Expert opinion on investigational drugs (2020)
GLP-1Ragonists offer a complementary and enhanced therapeutic value to other drugs used to treat PD. Moreover, the use of the dual- or tri-agonist GLP-1-based mimetics may provide combinatory effects that are even more powerful than GLP-1R agonism alone. We advocate for further investigations into the repurposing of GLP-1R agonists and the development of classes of multi-agonists for PD treatment.
Keyphrases
  • combination therapy
  • replacement therapy
  • drug induced
  • smoking cessation